References
- Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 19: 1478–1484
- Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998; 9 Suppl 5: S73–S78
- Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Ruffer U, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998; 92: 4560–4567
- Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810–3821
- Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 2000; 11: 1105–1114
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
- Sieber M, Engert A, Diehl V. Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol 2000; 11: S81–S85
- Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D. for the German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
- Jaffe E S, Harris N L, Stein H, Vardiman J W. WHO Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
- Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860–1861
- Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997; 8: 143–148
- Armstrong A A, Alexander F E, Cartwright R, Angus B, Krajewski A S, Wright D H, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia 1998; 12: 1272–1276
- Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945; 1: 80–83
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
- Stein H, Delsol G, Pileri S. Hodgkin lymphoma. E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, Lyon 2001; 237–253, World Health Organization Classification of Tumours, Pathology & Genetics, Tumours of Haematopoietic and Lymphoid Tissues
- Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696–702
- Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D, et al. Expression of p53, p. 21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol 2000; 15: 445–453
- Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943–953
- Jarrett R F, Stark G L, White J, Alexander F E, Krajewski A S, Freeland J, et al. for the Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005; 106: 2444–2451
- Keegan T H, Glaser S L, Clarke C A, Gulley M L, Craig F E, Digiuseppe J A, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005; 23: 7604–7613